WAIVER OF SERVICE OF SUMMONS

Pursuant to the Court's Order of January 21, 2014 in *In re Incretin-Based Therapies Products Liability Litigation*, counsel for Novo Nordisk Inc. hereby acknowledges receipt of the Complaint and waives service of the summons under Rule 4 of the Federal Rules of Civil Procedure in the action of Michael A. Morrow, Individually and as Successor-in-Interest of Sara Jean Trevathan Morrow v. Amylin Pharmaceuticals, LLC, Eli Lilly and Company, and Novo Nordisk Inc., which is case number 3:13-md-02452-AJB-MDD in the United States District Court for the Southern District of California.

Novo Nordisk Inc. hereby retains all defenses or objections to the lawsuit or to the jurisdiction or venue of the court except for objections based on a defect in the summons or in the service of the summons.

In accordance with the Court's Order referenced above, Novo Nordisk Inc.'s Answer to Consolidated Master Form Complaint automatically serves as the Answer in this action, and no further Answer is required.

By: _____

Raymond M. Williams (Bar No. 164068)
1650 Market Street, Suite 4900
Philadelphia, PA 19103
Tel: 215.656.3300
Fax: 215.656.3301
raymond.williams@dlapiper.com

For: Novo Nordisk Inc.

Date: October 13, 2014